“We wish to inform the exchange that the Company’s API manufacturing facility- D9 located at Plot No. 5, GIDC, Panoli, Gujarat was inspected by the USFDA. The inspection was conducted from March 10, 2025, to March 13, 2025,” JB Chemicals & Pharmaceuticals said in a regulatory filing.
The inspection, conducted from March 10 to March 13, 2025, concluded with no Form 483 issued.
“The company remains committed to producing quality products, embedding a quality culture across the organisation and continuously investing in systems, processes & training of its employees so that it can maintain the highest standards of quality and compliance for all its markets,” it added.Also Read: JB Chemicals aims to double contract manufacturing revenue to $100 million in four years
For the third quarter, JB Chemicals and Pharmaceuticals reported a 21.6% year-on-year (YoY) surge in net profit at ₹162.5 crore for the third quarter that ended December 31, 2024, compared to ₹133.6 crore in Q3 FY24.
The company’s revenue from operations increased 14.1% to ₹963.5 crore against ₹844.5 crore in the corresponding period of the preceding fiscal year. At the operating level, EBITDA was up 14.1% to ₹254.5 crore in the third quarter of this fiscal year over ₹223.1 crore year-on-year.
The EBITDA margin remained the same at 26.4% in the reporting quarter versus 26.4% in the year-ago quarter. EBITDA is earnings before interest, tax, depreciation, and amortisation.
Also Read: KKR is said to consider selling $750 million stake in JB Pharma
On Thursday (March 13), shares of JB Chemicals & Pharmaceuticals Ltd ended at ₹1,518.00, up by ₹13.30, or 0.88%, on the BSE.
